CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $40,883
- in 1 filing
Net +$959,111. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-10 | Dupont Jakob EVP, Head of R&D | Option exercise · Employee Stock Option (Right to Buy) | −5,000 | 257,500 | ||
| 2022-02-07 | Koppikar Utpal Chief Financial Officer | Sale | −2,496 | $14.46 | $36K | 155,702 |
| 2022-01-03 | Dupont Jakob EVP, Head of R&D | Option exercise | +5,000 | $9.58 | $48K | 95,594 |
| 2022-01-03 | Dupont Jakob EVP, Head of R&D | Sale | −5,000 | $16.01 | $80K | 90,594 |
| 2022-01-03 | Dupont Jakob EVP, Head of R&D | Option exercise · Employee Stock Option (Right to Buy) | −5,000 | 262,500 | ||
| 2021-12-01 | Dupont Jakob EVP, Head of R&D | Option exercise | +5,000 | $9.58 | $48K | 95,594 |
| 2021-12-01 | Dupont Jakob EVP, Head of R&D | Sale | −5,000 | $17.94 | $90K | 90,594 |
| 2021-12-01 | Dupont Jakob EVP, Head of R&D | Option exercise · Employee Stock Option (Right to Buy) | −5,000 | 267,500 | ||
| 2021-11-16 | Touchon Pascal President and CEO | Sale | −8,402 | $17.12 | $144K | 328,489 |
| 2021-11-16 | Newell Joe Chief Operations Officer | Sale | −3,332 | $17.12 | $57K | 113,097 |
| 2021-11-16 | Murugan Amar SVP, GC & Secretary | Sale | −2,124 | $17.12 | $36K | 87,540 |
| 2021-11-16 | Koppikar Utpal Chief Financial Officer | Sale | −3,655 | $17.12 | $63K | 157,714 |
| 2021-11-16 | Dupont Jakob EVP, Head of R&D | Sale | −2,199 | $17.12 | $38K | 90,594 |
| 2021-11-15 | Newell Joe Chief Operations Officer | Option exercise | +3,500 | $12.15 | $43K | 123,429 |
| 2021-11-15 | Newell Joe Chief Operations Officer | Sale | −7,000 | $17.71 | $124K | 116,429 |
| 2021-11-15 | Newell Joe Chief Operations Officer | Option exercise · Employee Stock Option (Right to Buy) | −2,792 | 32,083 | ||
| 2021-11-15 | Newell Joe Chief Operations Officer | Option exercise · Employee Stock Option (Right to Buy) | −708 | 9,917 | ||
| 2021-11-04 | Fust Matthew K Director | Sale | −13,354 | $19.50 | $260K | 31,500 |
| 2021-11-02 | Dupont Jakob EVP, Head of R&D | Option exercise | +5,000 | $9.58 | $48K | 97,793 |
| 2021-11-02 | Dupont Jakob EVP, Head of R&D | Sale | −5,000 | $16.41 | $82K | 92,793 |
Page 12 of 17 · 334 trades